Key Takeaways
- Record quarter, margin blip: Revenue surged 65% YoY to a record INR246 crores, but Q4 gross margin fell to ~26% from ~32% on solvent price spikes, dragging EBITDA margin down sequentially.
- Ibuprofen is the growth engine: Sales nearly doubled QoQ in Q4 and the company targets 25%–28% of total revenue in FY25, up from a smaller base, as last year's capex capacity comes online.
- FY25 guidance is concrete and bullish: Management guided for 20%–25% top-line growth and an EBITDA margin recovery to 20% plus, implying a ~400 bps improvement from the FY24 full-year figure of 16.4%.
- Backward integration is the margin story: Over half of the INR150 crore FY25 capex targets backward integration, which management credits for raw material cost control and competitive resilience even as product prices fall.
- What to watch next quarter: Whether solvent price volatility settles as management expects, the pace of Ibuprofen's march toward 65% capacity utilization, and any early signs that the 20% EBITDA margin target is on track.
Ibuprofen: The Growth Bet
- Sales trajectory: Q4 FY24 sales nearly doubled QoQ, driven by a widening customer base and increasing traction with existing customers across new geographic segments.
- FY25 ambition: Management expects Ibuprofen to reach 25%–28% of total revenue in FY25, up from a smaller contribution in FY24, as the significant capex from last year translates into volume.
- Capacity utilization: The target is to hit 65%–70% utilization in FY25, conservatively 65%, leaving headroom for further volume growth before new capex is needed.
- Pricing has found a floor: Prices have stabilized at the lower level, and the company is profitable even at those prices while gaining market share.
- Competitive moat: As a 35-year-old company with quality acceptable to regulated markets, SMS has established positions and has not lost market share in any key product over the last 2–3 years, despite increasing competition and falling prices.
Vamsi Krishna: "Definitely, I think ibuprofen quarter over quarter, again, as we discussed in the last conference call, we are adding more customers in every quarter. We are adding more geographic segments as well."
Margin Walk & Recovery Plan
- Q4 gross margin decline: Gross margin fell to ~26% from ~32% purely because of raw material price increases, specifically solvents.
- Q4 EBITDA margin decline: The gross margin hit plus a one-time increase in employee expenses (year-end provisions and managerial remuneration) pulled EBITDA margin down sequentially.
- FY25 recovery promise: Management expects EBITDA margins to return to 20% plus, a ~400 bps improvement over the FY24 full-year figure of 16.4%, driven by cost optimization and operating leverage from higher volumes.
- Gross margin target: Anticipating a 25% improvement in gross margin for FY25, though the base and calculation were not fully detailed.
- Solvent price risk: Management expects solvent price volatility to settle in the next one to two months, but Q1 may still see ups and downs, making this a near-term watchpoint.
Vamsi Krishna: "No, we will go back to the 20 plus percentage as it was previously there. So, EBITDA margins will definitely improve going forward."
Capex: Backward Integration First
- FY25 capex envelope: ~INR150 crores, to be deployed over 8–9 months, funded through internal approvals, term loans, and the INR114.3 crore convertible equity warrant issuance completed in Q4.
- Allocation: More than 50%–60% is earmarked for backward integration, with the remaining ~40% for a new hydrogenation block, warehouse expansion, and raw material storage.
- Revenue contribution timeline: Management anticipates the new capex will start contributing from FY26, not FY25, so the near-term growth story rests on ramping up utilization of existing assets.
- Incremental return profile: Because the capex adds value to existing revenue streams (backward integration), management expects it to generate more revenue compared to the existing asset base.
- Pipeline beyond Ibuprofen: After consolidating the Ibuprofen business over the next six months, the company is evaluating a few other projects and will disclose details later.
Product & Therapeutic Mix
- Anti-diabetic segment: The standout performer in FY24, with sales volume growth driven by new product introductions and an expanding customer base; a pipeline of products under development and patent-expiry opportunities in new regulated markets are expected to sustain momentum.
- ARV segment: Contribution as a percentage of total revenue decreased because total revenue grew and dependency was reduced; absolute sales de-growth was "very minor." The mix shift between lower-margin sale mode and higher-margin contract manufacturing creates quarter-over-quarter margin differences.
- R&D allocation: ~40% of the R&D budget focuses on cost reduction, process improvements, and backward integration for existing products; the remaining 60% targets new and niche products, prioritized by patent expiries and customer inquiries.
- Therapeutic focus: The company will stay within existing therapeutic areas to add newer-generation products; as an API manufacturer, it is not majorly focused on expanding into new therapeutic categories.
- ROW market push: Targeting African and Latin American regions where presence has been lacking is a focus area for the year, adding a geographic growth lever alongside product expansion.
Competitive & Pricing Dynamics
- Pricing is the key risk: Management acknowledged that pricing will be a key issue going forward, with mitigation resting on backward integration and cost optimization, the same R&D-driven strategy that has preserved market share over the last 2–3 years.
- Market share resilience: Despite increasing competition and falling prices, the company has not lost market share in any key product, a track record it attributes to quality acceptable for regulated markets and continuous cost work.
- ARV margin complexity: The mix of sale-mode (lower margin, adds to topline) and contract-manufacturing (higher margin, adds only to bottom line) creates quarter-over-quarter differences in reported margins that are structural, not operational.
- Competitive disclosure gap: When asked about the competitive landscape evolution, management spoke generally about its 35-year track record and quality positioning but did not name specific competitors or quantify market share changes.
Vamsi Krishna: "It has stabilized now, actually. I mean, it has normalized in the downside, but we are able to compete. We are able to get good market share, even at those prices."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line growth | 20%–25% revenue growth (conservatively ~25%) | FY25 |
| EBITDA margin | Recover to 20% plus (~400 bps improvement from FY24's 16.4%) | FY25 |
| Ibuprofen revenue share | Reach 25%–28% of total revenue | FY25 |
| Ibuprofen capacity utilization | Hit 65%–70% (conservatively 65%) | FY25 |
| Capex deployment | ~INR150 crores, 50%–60% toward backward integration | Deployed over 8–9 months in FY25 |
| Capex revenue contribution | New capex starts contributing to revenue | FY26 |
| Medium-term revenue target | Reach INR1,200–INR1,300 crores | Next 3–4 years |
| Medium-term EBITDA margin | ~20%, dependent on product mix | Next 3–4 years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹246 cr, +65% YoY |
| Full-year revenue | ₹709 cr, +36% YoY from ₹522 cr in FY23 |
| EBITDA margin | 16.4% for FY24, +601 bps YoY |
| PAT | ₹17 cr, +178% YoY |
| Full-year PAT | ₹50 cr, turnaround from loss of ₹7 cr in FY23 |
| Gross margin | 26%, down from ~32% in prior quarters due to raw material and solvent price increases |
| Dividend | ₹0.4 per share, 40% of face value, highest ever announced |
| API segment revenue | ₹242.1 cr, 98.5% of consolidated revenue |
| API export share | 89% of API revenue, including deemed exports |
| Anti-diabetic share | 29% of total sales |
| Ibuprofen share | ~19% of FY24 revenue |
| ARV share | 16% of total sales in Q4, ~20% for full year |
| Capacity utilization | ~65% overall |
| Ibuprofen capacity utilization | ~40% in Q4, full-year average ~25% |
| FY25 revenue growth guidance | 20% to 25% |
| FY25 EBITDA margin target | ~20% |
| FY25 capex plan | ~₹150 cr, funded via internal accruals, term loans, and ₹114.3 cr equity warrants |
| 3–4 year revenue target | ₹1,200–₹1,300 cr |
| Ibuprofen FY25 revenue share target | 25% to 28% of total revenue |
| Ibuprofen FY25 capacity utilization target | 65% to 70%, conservatively 65% |
| R&D allocation | 40% cost optimization and backward integration, 60% new and niche products |
| VKT Pharma investment | 36.5% stake, ₹45 cr; VKT top line ~₹96 cr |